Impact of Molecular Subtype Conversion of Breast Cancers after Neoadjuvant Chemotherapy on Clinical Outcome
Siew Kuan Lim, Moo Hyun Lee, In Hae Park, Ji Young You, Byung-Ho Nam, Byeong Nam Kim, Jungsil Ro, Keun Seok Lee, So-Youn Jung, Young Mee Kwon, Eun Sook Lee
Cancer Res Treat. 2016;48(1):133-141.   Published online 2015 Apr 7     DOI:
Citations to this article as recorded by Crossref logo
Negative Conversion of Progesterone Receptor Status after Primary Systemic Therapy Is Associated with Poor Clinical Outcome in Patients with Breast Cancer
Soomin Ahn, Hyun Jeong Kim, Milim Kim, Yul Ri Chung, Eunyoung Kang, Eun-Kyu Kim, Se Hyun Kim, Yu Jung Kim, Jee Hyun Kim, In Ah Kim, So Yeon Park
Cancer Research and Treatment.2018; 50(4): 1418.     CrossRef
Impact of Neoadjuvant Chemotherapy on Breast Cancer Subtype: Does Subtype Change and, if so, How?
Lucy M. De La Cruz, Michael O. Harhay, Paul Zhang, Stacy Ugras
Annals of Surgical Oncology.2018; 25(12): 3535.     CrossRef
Modern therapies and iatrogenic changes in breast pathology
Elena Provenzano, Sarah E Pinder
Histopathology.2017; 70(1): 40.     CrossRef
Biomarkers of residual disease after neoadjuvant therapy for breast cancer
Frederique Penault-Llorca, Nina Radosevic-Robin
Nature Reviews Clinical Oncology.2016; 13(8): 487.     CrossRef